These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 579188)

  • 21. A phase I study of cytembena.
    Frytak S; Moertel CG; Schutt AJ; Ahmann DL; Donadio JV; Weinshilboum RM
    Cancer; 1976 Mar; 37(3):1248-55. PubMed ID: 946591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
    J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.
    Clarke-Pearson DL; Van Le L; Iveson T; Whitney CW; Hanjani P; Kristensen G; Malfetano JH; Beckman RA; Ross GA; Lane SR; DeWitte MH; Fields SZ
    J Clin Oncol; 2001 Oct; 19(19):3967-75. PubMed ID: 11579118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Status report of Mayo Clinic studies.
    Edmonson JH
    Natl Cancer Inst Monogr; 1975 Oct; 42():167-8. PubMed ID: 1243994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of spirogermanium given daily.
    Legha SS; Ajani JA; Bodey GP
    J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of effects of cyclophosphamide, Cytembena, and Ypenyl in the treatment of inoperable ovarian carcinoma.
    Skoda V; Elis J; Jandová A; Laurová L; Novotná J; Perlík F
    Neoplasma; 1971; 18(5):471-2. PubMed ID: 5165867
    [No Abstract]   [Full Text] [Related]  

  • 27. Preliminary results with the new cytostatic Penberol in ovarian carcinoma.
    Novotná J; Andrysek O
    Neoplasma; 1980; 27(1):77-82. PubMed ID: 7374860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
    Edmonson JH; Frytak S; Letendre L; Kvols LK; Eagan RT
    Cancer Treat Rep; 1979; 63(11-12):2081-3. PubMed ID: 526941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
    Gore M; Rustin G; Schüller J; Lane SR; Hearn S; Beckman RA; Ross G
    Br J Cancer; 2001 Apr; 84(8):1043-6. PubMed ID: 11308251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
    Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral cytembena absorption and phase I--II studies.
    Neidhart JA; Staubus AE; Young D; Balcerzak SP; Malspes IL
    Cancer Treat Rep; 1978 Mar; 62(3):401-4. PubMed ID: 348307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combination of adriamycin and cis-diammine-dichloro-platinum (II) in the treatment of advanced, therapy-resistant, ovarian carcinoma (author's transl)].
    Cavalli F; Stoller U; Tschopp L; Sonntag RW; Brunner KW
    Dtsch Med Wochenschr; 1978 Jun; 103(22):927-31. PubMed ID: 350534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
    J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
    Denefrio JM; Vogel CL
    Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
    [No Abstract]   [Full Text] [Related]  

  • 38. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
    Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Single topotecan or in combination with other chemotherapeutic agents for 18 recurrent advanced ovarian cancer patients].
    Li H; Liu L; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):513-5. PubMed ID: 11859726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival of patients with advanced ovarian carcinoma treated with Penberol.
    Novotná J; Andrysek O; Kobilková J; Laurová L
    Neoplasma; 1983; 30(2):245-50. PubMed ID: 6302531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.